Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2022 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement in the transcript that indicates escalation of unit size, not just volume or price. The transcript is from Helios Technologies Q1 2022 earnings call. Management discusses strong demand, market share gains, supply chain issues, etc. They mention acquisitions, but that's not about the same offering. They talk about growth, but not about individual deal size increasing. Let's scan the transcript for any mention of larger orders, bigger contracts, etc. The CEO Josef Matosevic says: "Our innovative higher value solutions are proving to be sticky with our customers, and are building the loyalty." That's about stickiness, not size. He mentions "we continue to take market share." That's volume. He mentions "our ability to deliver top-tier industry lead times helps us beat the competition and we continue to take market share." No mention of deal size. Tricia Fulton talks about pricing, cost, etc. She mentions "we are seeing pricing pressures in areas that we maybe didn't anticipate, but we're also seeing, as we pointed out, really strong demand." That's about pricing and demand, not unit size. There is no mention of average order size, contract value, or any comparison of the size of new deals versus past deals. The only thing about acquisitions is the PME acquisition, but that's a bolt-on acquisition, not the same offering. They talk about "system sales" but that's about cross-selling, not necessarily larger individual orders. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. There is no such description. The management talks about strong demand, market share gains, and supply chain challenges, but nothing about the individual size of orders or contracts escalating. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.